Suppr超能文献

一线放化疗后完全缓解可预测结外 NK/T 细胞淋巴瘤的生存。

Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma.

机构信息

Department of Hematology, Centre Hospitalier universitaire Lyon Sud, Pierre Benite, France.

出版信息

J Hematol Oncol. 2012 Jun 8;5:27. doi: 10.1186/1756-8722-5-27.

Abstract

BACKGROUND

Extranodal nasal-type NK/T-cell lymphoma is a rare and severe disease. Considering the rarity of this lymphoma in Europe, we conducted a multicentric retrospective study on nasal-type NK/T cell lymphoma to determine the optimal induction strategy and identify prognostic factors.

METHODS

Thirty-six adult patients with nasal-type NK/T-cell lymphoma were recruited and assessed. In total, 80 % of patients were classified as having upper aerodigestive tract NK/T-cell lymphoma (UNKTL) and 20 % extra-upper aerodigestive tract NK/T-cell lymphoma (EUNKTL).

RESULTS

For advanced-stage disease, chemotherapy alone (CT) was the primary treatment (84 % vs. 10 % for combined CT + radiation therapy (RT), respectively), while for early-stage disease, 50 % of patients received the combination of CT + RT and 50 % CT alone. Five-year overall survival (OS) and progression-free survival (PFS) rates were 39 % and 33 %. Complete remission (CR) rates were significantly higher when using CT + RT (90 %) versus CT alone (33 %) (p < 0.0001). For early-stage disease, CR rates were 37 % for CT alone versus 100 % for CT + RT. Quality of response was significantly associated with survival, with 5-year OS being 80 % for CR patients versus 0 % for progressive disease patients (p < 0.01).

CONCLUSION

Early RT concomitantly or sequentially with CT led to improved patient outcomes, with quality of initial response being the most important prognosticator for 5-year OS.

摘要

背景

结外鼻型 NK/T 细胞淋巴瘤是一种罕见且严重的疾病。考虑到这种淋巴瘤在欧洲的罕见性,我们进行了一项多中心回顾性研究,以确定鼻型 NK/T 细胞淋巴瘤的最佳诱导策略并确定预后因素。

方法

共招募并评估了 36 例成人鼻型 NK/T 细胞淋巴瘤患者。80%的患者被归类为上呼吸道 NK/T 细胞淋巴瘤(UNKTCL),20%为上呼吸道外 NK/T 细胞淋巴瘤(EUNKTCL)。

结果

对于晚期疾病,单独化疗(CT)是主要治疗方法(分别为 84%和 10%的患者接受 CT+放疗(RT)联合治疗),而对于早期疾病,50%的患者接受 CT+RT 联合治疗,50%的患者接受 CT 单独治疗。5 年总生存率(OS)和无进展生存率(PFS)分别为 39%和 33%。CR 率在 CT+RT 时显著高于 CT 单独治疗(90% vs. 33%,p<0.0001)。对于早期疾病,CT 单独治疗的 CR 率为 37%,而 CT+RT 的 CR 率为 100%。缓解质量与生存显著相关,CR 患者的 5 年 OS 为 80%,而进展性疾病患者为 0%(p<0.01)。

结论

早期 RT 与 CT 同时或序贯应用可改善患者结局,初始反应质量是 5 年 OS 的最重要预后因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e81d/3416641/ed36fb924216/1756-8722-5-27-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验